L-myc gene polymorphism and risk of thyroid cancer
I. Yaylim-Eraltan1, N. Bozkurt1, A. Ergen1, U. Zeybek1,
O. Ozturk1, S. Arikan2, Y. Erbil3, I. Uslu4,
H. Camlica5, T. Isbir1, *
1Institute of Experimental Medical Research,Department of Molecular
Medicine, Istanbul University, Istanbul, Turkey 2Istanbul Research and Education Hospital, Surgery Clinic, Istanbul, Turkey 3Istanbul University, Istanbul Medical Faculty, Department of General Surgery,
Istanbul, Turkey 4Istanbul University, Cerrahpasa Medical Faculty, Department of Nuclear
Medicine, Istanbul, Turkey 5Istanbul University, Institute of Oncology, Division of Cancer Epidemiology
and Biostatistics, Istanbul, Turkey
Abstract. L-myc gene polymorphism is a representative genetic trait responsible for an
individual’s susceptibility to several cancers. However, there have been no reports
concerning the association between thyroid cancer and L-myc gene polymorphism. Aim: To
analyze the distribution of L-myc gene polymorphism in Turkish patients with thyroid
disorders and thyroid cancers. Methods: We used a molecular genotyping method, polymerase
chain reaction-based restriction fragment length polymorphism (PCR-RFLP). We studied 138
patients of whom 47 had multinodular goiter, 13 had follicular cancer and 69 had papillar
cancer, in comparison with control group of 109 healthy individuals. Results: No
significant difference in the distribution of genotypes was observed between thyroid
patients and controls. Carrying SS or LS genotype revealed a 1.96-fold (95% CI
0.573–6.706) risk for the occurrence of follicular cancer when compared with controls,
and 3.11-fold (95% CI 0.952–10.216), when compared with multinodular goiter patients (p
= 0.04). Conclusion: We suggest that L-myc genotype profiling together with other
susceptibility factors, may be useful in the screening for thyroid nodular malignancy.